Cybermedlife - Therapeutic Actions Dietary Modification - Glutamic and Aspartic Acid Reduced (G.A.R.D)

The effect of dietary glutamate on fibromyalgia and irritable bowel symptoms.

Abstract Title: The effect of dietary glutamate on fibromyalgia and irritable bowel symptoms. Abstract Source: Clin Exp Rheumatol. 2012 Jul 4. Epub 2012 Jul 4. PMID: 22766026 Abstract Author(s): Kathleen F Holton, Douglas L Taren, Cynthia A Thomson, Robert M Bennett, Kim D Jones Article Affiliation: Departments of Orthopaedics and Rehabilitation, Oregon Health&Science University, Portland, OR, USA. This email address is being protected from spambots. You need JavaScript enabled to view it.. Abstract: OBJECTIVES: To examine the effects of a challenge with monosodium glutamate (MSG) as compared to placebo on the symptoms of fibromyalgia (FM), in participants who initially experienced>30% remission of symptoms on an excitotoxin elimination diet. METHODS: Fifty-seven FM patients who also had irritable bowel syndrome (IBS) were placed on a 4-week diet that excluded dietary additive excitotoxins including MSG and aspartame. Thirty-seven people completed the diet and 84% of those reported that>30% of their symptoms resolved, thus making them eligible to proceed to challenges. Subjects who improved on the diet were then randomised to a 2-week double-blind placebo-controlled crossover challenge with MSG or placebo for 3 consecutive days each week. The primary outcome measure was total symptom score. Secondary outcome measures included visual analogue pain scales (VAS for FM and IBS), an IBS Quality of Life Questionnaire (IBS QOL) and the Fibromyalgia Impact Questionnaire-Revised (FIQR). Repeated measures ANOVA was used to analyse crossover challenge results. RESULTS: The MSG challenge, as compared to placebo, resulted in a significant return of symptoms (total symptom score, p<0.02); a worsening of fibromyalgia severity as determined by the FIQR (p<0.03); decreased quality of life in regards to IBS symptoms (IBS QOL, p<0.05); and a non-significant trend toward worsening FM pain based on visual analogue scale (VAS, p<0.07). CONCLUSIONS: These findings suggest that dietary glutamate may be contributing to FM symptoms in some patients. Future research on the role of dietary excitotoxins in FM is warranted. Article Published Date : Jul 03, 2012
Therapeutic Actions DIETARY MODIFICATION Glutamic and Aspartic Acid Reduced (G.A.R.D)

NCBI pubmed

Enhanced adsorption performance of aspartic acid intercalated Mg-Zn-Fe-LDH materials for arsenite.

Related Articles Enhanced adsorption performance of aspartic acid intercalated Mg-Zn-Fe-LDH materials for arsenite. Dalton Trans. 2018 Mar 20;: Authors: Lu H, Lu T, Zhang H, Qiu Y, Yin D, Zhu Z Abstract A series of hydrophobic and hydrophilic amino acid (aspartic acid, phenylalanine, glutamic acid, and proline) intercalated LDH materials were synthesized and characterized. The results of batch experiments showed that Mg7Zn1Fe4-Asp-LDH and Mg7Zn1Fe4-Phe-LDH showed good adsorption performances for both arsenate and arsenite in aqueous solutions. The effects of various experimental conditions have been investigated by the batch test, which included the effects of initial pH, arsenic concentration, contact time and coexisting ions. For Mg7Zn1Fe4-Asp-LDH under the optimal experimental conditions, the maximum adsorption capacity of As(iii) and As(v) reached 94.81 mg g-1 and 57.42 mg g-1, respectively. It showed a higher adsorption capacity for As(iii) than that for As(v), which is of great significance to remove the trivalent arsenic species with higher toxicity. When the dosage of Mg7Zn1Fe4-Asp-LDH was 0.8 g L-1, the concentration of As(iii) in the aqueous solution could be reduced from 2 mg L-1 to below 10 μg L-1.When Mg-Zn-Fe-Asp-LDH was applied in practical water samples with a dosage of 0.2 g L-1, the residual concentrations of arsenic in three actual water samples were all lower than 10 μg L-1 after adsorption. The column test showed that 1.0 g of Mg7Zn1Fe4-Asp-LDH could continuously treat 2.6 L of As(iii) aqueous solution (2 mg L-1) and reduced the concentration of As(iii) to below 10 μg L-1 or handle 0.4 L of arsenic-contaminated (10 mg L-1, As(iii) : As(v) = 1 : 1) water, and the effluent concentration was below 10 μg L-1. Compared with the previously reported hydrophobic amino acid intercalated LDHs, aspartic acid (hydrophilic amino acid) intercalated LDH has a good removal efficiency for arsenic. The synthesized Mg7Zn1Fe4-Asp-LDH is considered to be a potentially functional material that can be used to treat arsenic contamination in water. PMID: 29557460 [PubMed - as supplied by publisher]